Mechanistic comparison of atuveciclib and KN 92 [Supplementary Concept] KN 93 isomer; based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
3
Shared Targets
13%
Jaccard Similarity
16%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
atuveciclib and KN share 3 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.130 means 13% of the combined target set is bound by both compounds. The IDF-weighted score of 0.157 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do atuveciclib and KN have in common?
atuveciclib and KN share 3 molecular targets with a Jaccard similarity of 13%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can atuveciclib and KN be combined?
atuveciclib and KN share 3 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: atuveciclib or KN?
Both atuveciclib and KN have substantial PubMed research. View their individual profiles for full evidence scores.